Skip to content

Aegerion Pharmaceuticals’ Orphan Drug Juxtapid (Lomitapide): Medical Marketing & Media Perspective

December 27, 2012

Medical Marketing & Media publishes a December 26, 2012 article titled, “Drug for ultrarare lipid disorder OK’d by FDA’’, on the recent FDA approval of Aegerion Pharmaceuticals’ orphan drug Juxtapid (Lomitapide) for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) :

– Juxtapid is the 1st to market drug for treatment of HoFH

– Estimates 3,000 HoFH patients in US and another 3,000 in EU

– Jefferies analyst Eun Yang forecasts “ … revenue from Lomitapide for HoFH starting in 2013 (commercial launches in the US/EU in 1Q2013/2H2013) with peak sales potential of approximately $240M/$180M, respectively ….”

– Also, Yang says that Aegerion Pharmaceuticals will focus their commercial efforts at first on apheresis treatment centers and their sales force will detail about 400 Lipidologists in the US & 500 in the EU.

Next Catalyst

– Aegerion Pharmaceuticals presents at the JP Morgan Healthcare Conference, January 7 – 10, 2013 in San Francisco.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: